Сегодня наши сограждане медикализированы примерно в такой же степени, как и 50 лет назад. Снижение приема бензодиазепинов более чем на 50% было компенсировано аналогичным увеличением продаж СИОЗС27. СИОЗС используется почти для всех тех же состояний, что и бензодиазепины. Теперь психиатрам слишком удобно заявлять, что многое из того, что они ранее – когда еще было можно выписывать бензодиазепины – называли тревогой, на самом деле было депрессией, так что теперь они могут рекомендовать СИОЗС тем же пациентам. Пересадка пациентов с тревожными расстройствами с бензодиазепинов на СИОЗС произошла несмотря на отсутствие доказательств ее пользы27.
Мы стали свидетелями роста сомнительных показаний для СИОЗС, как это ранее было с бензодиазепинами, а до этого – с барбитуратами, хотя все эти лекарства вызывают зависимость51, 99, 104. До 2003 года Британский лекарственный регулятор лгал, что СИОЗС не вызывают зависимости, но в том же году ВОЗ опубликовала доклад, в котором отметила, что три СИОЗС (флуоксетин, пароксетин и сертралин) входят в топ-30 лекарств с наивысшим потенциалом лекарственной зависимости, о которой когда-либо сообщалось62.
Ссылки
1. Bass A. Side Effects – a prosecutor, a whistleblower, and a bestselling antidepressant on trial. Chapel Hill: Algonquin Books; 2008.
2. Caplan P.J. They Say You’re Crazy: how the world’s most powerful psychiatrists decide who’s normal. Jackson: Da Capo Press; 1995.
3. Angell M. ‘The illusions of psychiatry’: an exchange. New York Rev Books. 2011 Aug 18.
4. Moynihan R. Medicalization. A new deal on disease definition. BMJ. 2011; 342: d2548.
5. Harris G., Carey B., Roberts J. Psychiatrists, children and drug industry’s role. New York Times. 2007 May 10.
6. Insel T.R. Psychiatrists’ relationships with pharmaceutical companies: part of the problem or part of the solution? JAMA. 2010; 303: 1192–3.
7. Moynihan R. Is the relationship between pharma and medical education on the rocks? BMJ. 2008; 337: 484–5.
8. Watts G. More psychiatrists attack plans for DSM-5. BMJ. 2012; 344: e3357.
9. Moynihan R., Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
10. Boseley S. Prozac, used by 40m people, does not work say scientists. The Guardian. 2008 Feb 26.
11. Brown J., O’Brien P.M.S., Marjoribanks J., et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2: CD001396.
12. [Work environment and treatment modalities in Danish psychiatry]. Nordjyske Medier; 2007.
13. Total sales of medicinal products. Danish Medicines Agency. 2011.
14. IMS Health reports U.S. prescription sales grew 51. percent in 2009, to $3003. billion. IMS Health press release. 2010 April 1.
15. Kessler R.C., Demler O., Frank R.G., et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005; 352: 2515–23.
16. Spence D. The psychiatric oligarchs who medicalise normality. BMJ. 2012; 344: e3135.
17. Gross J. Checklist for camp: bug spray, sunscreen, pills. New York Times. 2006 July 16.
18. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
19. Schwarz A. Attention disorder or not, pills to help in school. New York Times. 2012 Oct 9.
20. GFK Denmark. [Focus group about treatment of ADHD in children and adolescents]. Letter. 2011 Nov 23.
21. Whitaker R. Anatomy of an Epidemic. New York: Broadway Paperbacks; 2010.
22. Morbidity and Mortality Weekly Report. Current depression among adults – United States, 2006 and 2008. JAMA. 2010; 304: 2233–5.
23. The Patient Health Questionnaire (PHQ-9). Available online at: Available online at: www.agencymeddirectors.wa.gov/Files/depressoverview.pdf (accessed 20 October 2012).
24. Healy D. Let them eat Prozac. New York: New York University Press; 2004.
25. Frances A. Antidepressant use has gone crazy: bad news from the CDC. Psychiatric Times. 2011 Oct 28.
26. Friedman R.A. Grief, depression, and the DSM-5. N Engl J Med. 2012; 366: 1855–7.
27. Nielsen M., Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. Int J Risk Saf Med. 2011; 23: 125–32.
28. Open letter to DSM-5. Online petition. Available online at: www.ipetitions.com/petition/dsm5/.
29. Spence D. Bad medicine: bipolar II disorder. BMJ. 2011; 342: d2767.
30. Martin A., Young C., Leckman J.F., et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004; 158: 773–80.
31. Shea S.E., Gordon K., Hawkins A., et al. Pathology in the Hundred Acre Wood: a neurodevelopmental perspective on A.A. Milne. CMAJ. 2000; 163: 1557–9.
32. The creation of the Prozac myth. The Guardian. 2008 Feb 27.
33. Spence D. Bad medicine: adult attention-deficit/hyperactivity disorder. BMJ. 2011; 343: d7244.
34. Aagaard L., Hansen E.H. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat. 2011; 7: 729–44.
35. More fraud from drug giant GlaxoSmithKline companies – court documents show. Child Health Safety. 2010 Dec 1.
36. Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.
37. Nemeroff C.B., Mayberg H.S., Krahl S.E., et al. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacol. 2006; 31: 1345–55.
38. Volpe M. Dr. Charles Nemeroff and Emory University’s culture of corruption. The Provocateur. 2009 July 10.
39. Nugent T. Profi le in courage: A beleaguered whistle-blower physician fights for patients and jobs – and wins. Opednews. 2012 Nov 1.
40. Keller M.B., McCullough J.P., Klein D.N., et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000; 342: 1462–70.
41. Angell M. Is academic medicine for sale? N Engl J Med. 2000; 342: 1516–8.
42. Larson J.C., Ensrud K.E., Reed S.D., et al. Effi cacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011; 305: 267–74.
43. Coupland C., Dhiman P., Morriss R., et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011; 343: d4551.
44. McHugh P.R., Slavney P.R. Mental illness – comprehensive evaluation or checklist? N Engl J Med. 2012; 366: 1853–5.
45. Kleinman A. Rebalancing academic psychiatry: why it needs to happen – and soon. Br J Psych. 2012; 201: 421–2.
46. Lacasse J.R., Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2005; 2: e392.
47. Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
48. Castrén E. Is mood chemistry? Nat Rev Neurosci. 2005; 6: 241–6.
49. Andrews P.W., Kornstein S.G., Halberstadt L.J., et al. Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol. 2011; 2: 159.
50. Medawar C., Herxheimer A., Bell A., et al. Paroxetine, Panorama and user reporting of ADRs: Consumer intelligence matters in clinical practice and post-marketing drug surveillance. Int J Risk Saf Med. 2002; 15: 161–9.
51. Nielsen M., Hansen E.H., Gøtzsche P.C. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction. 2012; 107: 900–8.
52. Medawar C., Herxheimer A.. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med. 2003/2004; 16: 5–19.
53. El-Mallakh R.S., Gao Y., Jeannie Roberts R. Tardive dysphoria: the role of long term antidepressant use in inducing chronic depression. Med Hypotheses. 2011; 76: 769–73.
54. Moore T.J., Glenmullen J., Furberg C.D. Prescription drugs associated with reports of violence towards others. PLoS One. 2010; 5: e15337.
55. Healy D. Reply to D.Wilkinson – Loss of anxiety and increased aggression in a 15-year-old boy taking fluoxetine. J Psychopharmacol. 1999; 13: 421.
56. Orriols L., Delorme B., Gadegbeku B., et al. Prescription medicines and the risk of road traffic crashes: a French registry-based study. PLoS Med. 2010; 7: e1000366.
57. FDA Approved Labeling Text for NDA 21-875/NUVIGIL™ (armodafinil) Tablets. 2007 June15.
58. Thombs B.D., Arthurs E., El-Baalbaki G., et al. Risk of bias from inclusion of patients who already have diagnosis of or are undergoing treatment for depression in diagnostic accuracy studies of screening tools for depression: systematic review. BMJ. 2011; 343: d4825.
59. Gilbody S., House A., Sheldon T. Screening and case finding instruments for depression. Cochrane Database Syst Rev. 2005; 4: CD002792.
60. Lundh A. [Is there evidence for screening for depression]? Ugeskr Læger. 2008; 170: 1479.
61. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.
62. Medawar C., Hardon A